Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib + Sorafenib in Unresectable HCC
NCT02240433Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galunisertib in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with LY2157299 Dose-Limiting Toxicities. Started Nov 2014; status: completed.
02
Drugs
galunisertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02240433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240433.